Literature DB >> 16098464

A conditional feedback loop regulates Ras activity through EphA2.

Madhu Macrae1, Richard M Neve, Pablo Rodriguez-Viciana, Christopher Haqq, Jennifer Yeh, Chira Chen, Joe W Gray, Frank McCormick.   

Abstract

The EphA2 receptor tyrosine kinase is frequently overexpressed in many cancers, including 40% of breast cancers. Here, we show that EphA2 is a direct transcriptional target of the Ras-Raf-MAPK pathway and that ligand-stimulated EphA2 attenuates the growth factor-induced activation of Ras. Thus, a negative feedback loop is created that regulates Ras activity. Interestingly, the expression of EphA2 and ephrin-A1 is mutually exclusive in a panel of 28 breast cancer cell lines. We show that the MAPK pathway inhibits ephrin-A1 expression, and the ligand expression inhibits EphA2 levels contributing to the receptor-ligand reciprocal expression pattern in these cell lines. Our results suggest that an escape from the negative effects of this interaction may be important in the development of cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098464     DOI: 10.1016/j.ccr.2005.07.005

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  115 in total

1.  Cancer cells exploit the Eph-ephrin system to promote invasion and metastasis: tales of unwitting partners.

Authors:  Bingcheng Wang
Journal:  Sci Signal       Date:  2011-05-31       Impact factor: 8.192

2.  Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.

Authors:  Justin M Drake; Nicholas A Graham; Tanya Stoyanova; Amir Sedghi; Andrew S Goldstein; Houjian Cai; Daniel A Smith; Hong Zhang; Evangelia Komisopoulou; Jiaoti Huang; Thomas G Graeber; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

Review 3.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

4.  Profiling signaling polarity in chemotactic cells.

Authors:  Yingchun Wang; Shi-Jian Ding; Wei Wang; Jon M Jacobs; Wei-Jun Qian; Ronald J Moore; Feng Yang; David G Camp; Richard D Smith; Richard L Klemke
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-09       Impact factor: 11.205

5.  Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.

Authors:  Roberta Noberini; Mitchell Koolpe; Satyamaheshwar Peddibhotla; Russell Dahl; Ying Su; Nicholas D P Cosford; Gregory P Roth; Elena B Pasquale
Journal:  J Biol Chem       Date:  2008-08-26       Impact factor: 5.157

Review 6.  Regulation and misregulation of Eph/ephrin expression.

Authors:  Dina N Arvanitis; Alice Davy
Journal:  Cell Adh Migr       Date:  2012-03-01       Impact factor: 3.405

Review 7.  Therapeutic targeting of EPH receptors and their ligands.

Authors:  Andrew W Boyd; Perry F Bartlett; Martin Lackmann
Journal:  Nat Rev Drug Discov       Date:  2014-01       Impact factor: 84.694

Review 8.  Eph receptor signaling and ephrins.

Authors:  Erika M Lisabeth; Giulia Falivelli; Elena B Pasquale
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-09-01       Impact factor: 10.005

Review 9.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

10.  EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.

Authors:  Philip D Dunne; Sonali Dasgupta; Patrick G Johnston; Sandra Van Schaeybroeck; Jaine K Blayney; Darragh G McArt; Keara L Redmond; Jessica-Anne Weir; Conor A Bradley; Takehiko Sasazuki; Senji Shirasawa; Tingting Wang; Supriya Srivastava; Chee Wee Ong; Ken Arthur; Manuel Salto-Tellez; Richard H Wilson
Journal:  Clin Cancer Res       Date:  2015-08-17       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.